curacle co.,ltd. (KOSDAQ:365270)
8,880.00
-220.00 (-2.42%)
At close: Oct 22, 2026
curacle co.,ltd. Revenue
curacle co.,ltd. had revenue of 7.18B KRW in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to 8.24B, up 627.54% year-over-year. In the year 2025, curacle co.,ltd. had annual revenue of 7.10M, down -99.57%. That makes curacle co.,ltd. the 39,220th largest company in the world by revenue and 2,456th in South Korea.
Revenue (ttm)
8.24B
Revenue Growth
+627.54%
P/S Ratio
23.88
Revenue / Employee
n/a
Employees
n/a
Market Cap
196.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.10M | -1.63B | -99.57% |
| Dec 31, 2024 | 1.63B | -8.66B | -84.14% |
| Dec 31, 2023 | 10.29B | 6.71B | 187.32% |
| Dec 31, 2022 | 3.58B | -2.67B | -42.72% |
| Dec 31, 2021 | 6.25B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 124.81B |
| ISU Abxis | 51.04B |
| Genome & Company | 24.46B |
| NIBEC | 22.60B |
| Bio Solution | 17.39B |
| S.Biomedics | 16.49B |
| IntoCell | 3.19B |
| Kangstem Biotech | 3.03B |